• Roberto Stasi.
• Regina Apostolorum Hospital, Department of Medical Sciences, Via S. Francesco, 50, 00041 Albano Laziale, Italy. roberto.stasi@uniroma2.it
• Expert Opin Biol Ther. 2008 Apr 1; 8 (4): 527-40.

BackgroundGemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal antibody.ObjectivesTo describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia.MethodsReview and summary of publications on gemtuzumab ozogamicin indexed in the PubMed electronic database.Results/ConclusionsGemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia. The side effect profile may be an improvement on conventional chemotherapy, except for a higher frequency of veno-occlusive disease or sinusoidal obstructive syndrome, especially after a subsequent haematopoietic stem cell transplantation. Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.

35 keywords...

hide…